Based on the provided data, there is no specific information regarding regulatory challenges associated with approving new antimicrobial agents targeting Bi(III)-bound NDM-1. The data primarily focus on the biochemical and biophysical characterization of NDM-1, including its interaction with Bi(III), enzyme inhibition assays, UV-vis spectroscopy, and enzyme kinetics, but do not address regulatory or legal considerations.

In general, developing and approving new antimicrobial agents, especially those targeting metallo-beta-lactamases like NDM-1, involves several regulatory challenges. These include demonstrating safety and efficacy through rigorous preclinical and clinical testing, ensuring manufacturing quality, and navigating complex approval pathways established by agencies such as the FDA or EMA. The unique aspect of targeting Bi(III)-bound NDM-1 may introduce additional considerations, such as the potential for off-target effects of metal-based inhibitors, the stability of the metal-protein complex, and the risk of resistance development, which could complicate regulatory review.

However, without specific data on regulatory issues from the provided sources, it is not possible to detail particular challenges related to this approach. The biochemical data suggest promising avenues for inhibitor development, but regulatory approval would require comprehensive safety and efficacy evaluations, which are not covered in the current dataset [Data: No relevant data references].